Advances in acute myeloid leukemia
LF Newell, RJ Cook - Bmj, 2021 - bmj.com
Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with
historically high mortality rates. The standard of care treatment remained unchanged for …
historically high mortality rates. The standard of care treatment remained unchanged for …
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Genomic investigations of acute myeloid leukemia (AML) have demonstrated that several
genes are recurrently mutated, leading to new genomic classifications, predictive …
genes are recurrently mutated, leading to new genomic classifications, predictive …
Cancer treatment and survivorship statistics, 2019
KD Miller, L Nogueira, AB Mariotto… - CA: a cancer journal …, 2019 - Wiley Online Library
The number of cancer survivors continues to increase in the United States because of the
growth and aging of the population as well as advances in early detection and treatment. To …
growth and aging of the population as well as advances in early detection and treatment. To …
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
RM Stone, SJ Mandrekar, BL Sanford… - … England Journal of …, 2017 - Mass Medical Soc
Background Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor
outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin …
outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin …
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic …
JE Cortes, FH Heidel, A Hellmann, W Fiedler, BD Smith… - Leukemia, 2019 - nature.com
Glasdegib is a Hedgehog pathway inhibitor. This phase II, randomized, open-label,
multicenter study (ClinicalTrials. gov, NCT01546038) evaluated the efficacy of glasdegib …
multicenter study (ClinicalTrials. gov, NCT01546038) evaluated the efficacy of glasdegib …
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
H Döhner, E Estey, D Grimwade… - Blood, The Journal …, 2017 - ashpublications.org
The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and
management of acute myeloid leukemia (AML) in adults, published in 2010, has found …
management of acute myeloid leukemia (AML) in adults, published in 2010, has found …
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for
diagnosis and management of acute myeloid leukemia (AML) in adults are widely …
diagnosis and management of acute myeloid leukemia (AML) in adults are widely …
Genomic classification and prognosis in acute myeloid leukemia
Background Recent studies have provided a detailed census of genes that are mutated in
acute myeloid leukemia (AML). Our next challenge is to understand how this genetic …
acute myeloid leukemia (AML). Our next challenge is to understand how this genetic …
Cancer treatment and survivorship statistics, 2016
The number of cancer survivors continues to increase because of both advances in early
detection and treatment and the aging and growth of the population. For the public health …
detection and treatment and the aging and growth of the population. For the public health …
Acute myeloid leukemia: a comprehensive review and 2016 update
I De Kouchkovsky, M Abdul-Hay - Blood cancer journal, 2016 - nature.com
Acute myeloid leukemia (AML) is the most common acute leukemia in adults, with an
incidence of over 20 000 cases per year in the United States alone. Large chromosomal …
incidence of over 20 000 cases per year in the United States alone. Large chromosomal …